Showing results (21-30 of 1,864) with videos related to
Sort By:
Pageof 187
Therapeutic Innovation & Regulatory Science|January 29, 2020
Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker-Driven Phase III TrialAkira Takazawa, Satoshi MoritaNagoya Journal of Medical Science|March 24, 2007
From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedsideJunichi Sakamoto, Satoshi MoritaPharmaceutical Statistics|January 27, 2018
Bayesian dose-finding phase I trial design incorporating historical data from a preceding trialKentaro Takeda, Satoshi MoritaTherapeutic Innovation & Regulatory Science|September 1, 2020
Correction to: Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker‑Driven Phase III TrialAkira Takazawa, Satoshi MoritaBiometrical Journal. Biometrische Zeitschrift|May 13, 2022
gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trialsKentaro Takeda, Satoshi Morita, Masataka TaguriJournal of the National Cancer Institute|May 10, 2015
Detecting overall survival benefit derived from survival postprogression rather than progression-free survivalSatoshi Morita, Kentaro Sakamaki, Guosheng YinJapanese Journal of Clinical Oncology|December 18, 2014
A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial)Wasaburo Koizumi, Satoshi Morita, Yuh SakataPhysical Review. E, Statistical, Nonlinear, and Soft Matter Physics|August 8, 2009
Quantum-thermal annealing with a cluster-flip algorithmSatoshi Morita, Sei Suzuki, Tota NakamuraStatistics in Medicine|May 14, 2014
Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulationSatoshi Morita, Hideharu Yamamoto, Yasuo SugitaniPharmaceutical Statistics|April 28, 2018
BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomesKentaro Takeda, Masataka Taguri, Satoshi MoritaPageof 187